Compare UPBD & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPBD | CMPS |
|---|---|---|
| Founded | 1986 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1996 | 2020 |
| Metric | UPBD | CMPS |
|---|---|---|
| Price | $18.27 | $12.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $32.25 | $25.38 |
| AVG Volume (30 Days) | 682.1K | ★ 4.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $4,695,061,000.00 | N/A |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $6.47 | N/A |
| P/E Ratio | $29.84 | ★ N/A |
| Revenue Growth | ★ 8.67 | N/A |
| 52 Week Low | $15.82 | $2.25 |
| 52 Week High | $28.03 | $14.76 |
| Indicator | UPBD | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 55.67 |
| Support Level | $16.99 | $5.37 |
| Resistance Level | $19.36 | N/A |
| Average True Range (ATR) | 0.57 | 1.02 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 45.47 | 42.60 |
Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has four operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions, Mexico segment offers lease-to-own stores in Mexico. The The Brigit segment offers various financial health products and tools to help users improve their financial health. The company derives a majority of its revenue from the Acima segment.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.